Graves' Disease Market - A Global and Regional Analysis: Focus on Treatment Type, Patient Age Group, End User, Country, and Region - Analysis and Forecast, 2025-2035
Graves’ disease is an autoimmune disorder that causes the thyroid gland to produce excessive amounts of thyroid hormones, leading to hyperthyroidism. It occurs when the immune system mistakenly attacks the thyroid by producing antibodies called thyroid-stimulating immunoglobulins (TSIs), which mimic the action of thyroid-stimulating hormone (TSH) and overstimulate the gland. This results in symptoms such as weight loss, rapid heartbeat, nervousness, heat intolerance, and tremors. Some individuals may also develop Graves’ ophthalmopathy, a condition that causes inflammation and bulging of the eyes. The disease is more common in women and typically develops between the ages of 30 and 50. Treatment options include antithyroid medications, radioactive iodine therapy, or surgery to reduce thyroid activity and restore hormonal balance.
The global Graves’ disease market is witnessing steady growth driven by the increasing prevalence of autoimmune thyroid disorders and rising awareness of thyroid dysfunctions. Graves’ disease, being the leading cause of hyperthyroidism, is gaining attention due to its growing incidence, particularly among middle-aged women and individuals with a family history of autoimmune diseases. The market expansion is primarily fueled by improved diagnostic capabilities, early screening programs, and the availability of more effective treatment modalities. As awareness of thyroid-related conditions increases, more patients are being diagnosed at earlier stages, supporting the demand for both pharmacologic and non-pharmacologic management options. Moreover, the link between Graves’ disease and related complications such as Graves’ ophthalmopathy has further driven research into advanced therapies that target immune-mediated mechanisms underlying the disease.
Additionally, technological progress and innovation in targeted and biologic therapies are propelling market growth. The use of monoclonal antibodies and small-molecule inhibitors designed to modulate immune responses offers greater efficacy and fewer side effects than traditional treatments like antithyroid drugs and radioactive iodine. Companies are also exploring gene therapy and immunomodulatory approaches to improve long-term disease control and reduce relapse rates. Continuous clinical trials and collaborations between pharmaceutical and biotechnology companies have expanded the therapeutic pipeline, introducing novel biologics and biosimilars aimed at improving safety and efficacy profiles. Furthermore, the availability of advanced imaging and diagnostic tools has enabled more precise disease monitoring and personalized treatment planning, improving clinical outcomes and patient quality of life.
However, high treatment costs and accessibility challenges remain significant restraints in the Graves’ disease market. Biologic and targeted therapies are expensive to manufacture and often lack widespread reimbursement, limiting patient access, particularly in emerging markets. The need for lifelong management and frequent monitoring adds to the overall economic burden. In addition, variability in treatment response and potential side effects from conventional therapies, such as corticosteroids or radioiodine, continue to pose clinical challenges. Addressing affordability and accessibility through cost-effective biosimilars, broader insurance coverage, and government healthcare initiatives will be crucial to sustaining market growth.
The competitive landscape of the Graves’ disease market includes major pharmaceutical and biotech players such as Amgen Inc. (through Horizon Therapeutics), Novartis AG, Roche Holding AG, Viridian Therapeutics Inc., and Immunovant Inc. These companies are actively developing next-generation biologic therapies and immune modulators that provide more targeted and durable treatment options. Strategic partnerships, research collaborations, and global expansion initiatives especially in North America, Europe, and Asia-Pacific—are accelerating clinical advancements and improving patient access. With ongoing innovations and a growing focus on personalized medicine, the Graves’ disease market is poised for substantial progress in the coming years.
Market Segmentation:
Segmentation 1: by Treatment Type
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.
The global Graves’ disease market is witnessing steady growth driven by the increasing prevalence of autoimmune thyroid disorders and rising awareness of thyroid dysfunctions. Graves’ disease, being the leading cause of hyperthyroidism, is gaining attention due to its growing incidence, particularly among middle-aged women and individuals with a family history of autoimmune diseases. The market expansion is primarily fueled by improved diagnostic capabilities, early screening programs, and the availability of more effective treatment modalities. As awareness of thyroid-related conditions increases, more patients are being diagnosed at earlier stages, supporting the demand for both pharmacologic and non-pharmacologic management options. Moreover, the link between Graves’ disease and related complications such as Graves’ ophthalmopathy has further driven research into advanced therapies that target immune-mediated mechanisms underlying the disease.
Additionally, technological progress and innovation in targeted and biologic therapies are propelling market growth. The use of monoclonal antibodies and small-molecule inhibitors designed to modulate immune responses offers greater efficacy and fewer side effects than traditional treatments like antithyroid drugs and radioactive iodine. Companies are also exploring gene therapy and immunomodulatory approaches to improve long-term disease control and reduce relapse rates. Continuous clinical trials and collaborations between pharmaceutical and biotechnology companies have expanded the therapeutic pipeline, introducing novel biologics and biosimilars aimed at improving safety and efficacy profiles. Furthermore, the availability of advanced imaging and diagnostic tools has enabled more precise disease monitoring and personalized treatment planning, improving clinical outcomes and patient quality of life.
However, high treatment costs and accessibility challenges remain significant restraints in the Graves’ disease market. Biologic and targeted therapies are expensive to manufacture and often lack widespread reimbursement, limiting patient access, particularly in emerging markets. The need for lifelong management and frequent monitoring adds to the overall economic burden. In addition, variability in treatment response and potential side effects from conventional therapies, such as corticosteroids or radioiodine, continue to pose clinical challenges. Addressing affordability and accessibility through cost-effective biosimilars, broader insurance coverage, and government healthcare initiatives will be crucial to sustaining market growth.
The competitive landscape of the Graves’ disease market includes major pharmaceutical and biotech players such as Amgen Inc. (through Horizon Therapeutics), Novartis AG, Roche Holding AG, Viridian Therapeutics Inc., and Immunovant Inc. These companies are actively developing next-generation biologic therapies and immune modulators that provide more targeted and durable treatment options. Strategic partnerships, research collaborations, and global expansion initiatives especially in North America, Europe, and Asia-Pacific—are accelerating clinical advancements and improving patient access. With ongoing innovations and a growing focus on personalized medicine, the Graves’ disease market is poised for substantial progress in the coming years.
Market Segmentation:
Segmentation 1: by Treatment Type
- Anti-Thyroid Medication
- Radioactive Iodine Therapy
- Surgery (Thyroidectomy)
- Targeted Immunotherapies & Biologics
- Ultrasound-Guided Thermal Ablation
- Pediatrics
- Adults
- Geriatrics
- Hospitals
- Specialty Clinics & Endocrinology Centers
- Ambulatory Surgical Centers
- Retail & Online Pharmacies
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.
Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL GRAVES’ DISEASE MARKET: INDUSTRY ANALYSIS
1.1 Market Overview and Ecosystem
1.2 Key Market Trends
1.2.1 Impact Analysis
1.3 Regulatory Landscape
1.4 Pipeline Analysis
1.5 Market Dynamics
1.5.1 Overview
1.5.2 Market Drivers
1.5.3 Market Restraints
1.5.4 Market Opportunities
2. GLOBAL GRAVES’ DISEASE MARKET (BY TREATMENT TYPE), VALUE ($MILLION), 2024-2035
2.1 Anti-Thyroid Medication
2.2 Radioactive Iodine Therapy
2.3 Surgery (Thyroidectomy)
2.4 Targeted Immunotherapies & Biologics
2.5 Ultrasound-Guided Thermal Ablation
3. GLOBAL GRAVES’ DISEASE MARKET (BY PATIENT AGE GROUP), VALUE ($MILLION), 2024-2035
3.1 Pediatrics
3.2 Adults
3.3 Geriatrics
4. GLOBAL GRAVES’ DISEASE MARKET (BY END USER), VALUE ($MILLION), 2024-2035
4.1 Hospitals
4.2 Specialty Clinics & Endocrinology Centers
4.3 Ambulatory Surgical Centers
4.4 Retail & Online Pharmacies
5. GLOBAL GRAVES’ DISEASE MARKET (BY REGION), VALUE ($MILLION), 2024-2035
5.1 North America
5.1.1 Market Dynamics
5.1.2 Market Sizing and Forecast
5.1.3 North America Graves’ Disease Market, by Country ($Million), 2024-2035
5.1.3.1 U.S.
5.1.3.2 Canada
5.2 Europe
5.2.1 Market Dynamics
5.2.2 Market Sizing and Forecast
5.2.3 Europe Graves’ Disease Market, by Country ($Million), 2024-2035
5.2.3.1 Germany
5.2.3.2 UK
5.2.3.3 France
5.2.3.4 Italy
5.2.3.5 Spain
5.2.3.6 Rest of Europe
5.3 Asia-Pacific
5.3.1 Market Dynamics
5.3.2 Market Sizing and Forecast
5.3.3 Asia-Pacific Graves’ Disease Market, by Country ($Million), 2024-2035
5.3.3.1 China
5.3.3.2 India
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.3.5 Rest-of-Asia Pacific
5.4 Latin America
5.4.1 Market Dynamics
5.4.2 Market Sizing and Forecast
5.4.3 Latin America Graves’ Disease Market, by Country ($Million), 2024-2035
5.4.3.1 Brazil
5.4.3.2 Mexico
5.4.3.3 Argentina
5.4.3.4 Rest-of-Latin America
5.5 Middle East and Africa
5.5.1 Market Dynamics
5.5.2 Market Sizing and Forecast
6. COMPETITIVE LANDSCAPE AND COMPANY PROFILES
6.1 Competitive Landscape
6.1.1 Mergers and Acquisitions
6.1.2 Partnership, Alliances and Business Expansion
6.1.3 New Offerings
6.1.4 Regulatory Activities
6.1.5 Funding Activities
6.2 Company Profiles
6.2.1 Horizon Therapeutics.
6.2.1.1 Overview
6.2.1.2 Top Products / Product Portfolio
6.2.1.3 Top Competitors
6.2.1.4 Target Customers/End-Users
6.2.1.5 Key Personnel
6.2.1.6 Analyst View
6.2.2 Novartis AG.
6.2.2.1 Overview
6.2.2.2 Top Products / Product Portfolio
6.2.2.3 Top Competitors
6.2.2.4 Target Customers/End-Users
6.2.2.5 Key Personnel
6.2.2.6 Analyst View
6.2.3 F. Hoffmann-La Roche Ltd.
6.2.3.1 Overview
6.2.3.2 Top Products / Product Portfolio
6.2.3.3 Top Competitors
6.2.3.4 Target Customers/End-Users
6.2.3.5 Key Personnel
6.2.3.6 Analyst View
6.2.4 Medtronic plc
6.2.4.1 Overview
6.2.4.2 Top Products / Product Portfolio
6.2.4.3 Top Competitors
6.2.4.4 Target Customers/End-Users
6.2.4.5 Key Personnel
6.2.4.6 Analyst View
6.2.5 GE HealthCare Technologies Inc.
6.2.5.1 Overview
6.2.5.2 Top Products / Product Portfolio
6.2.5.3 Top Competitors
6.2.5.4 Target Customers/End-Users
6.2.5.5 Key Personnel
6.2.5.6 Analyst View
6.2.6 Viridian Therapeutics Inc.
6.2.6.1 Overview
6.2.6.2 Top Products / Product Portfolio
6.2.6.3 Top Competitors
6.2.6.4 Target Customers/End-Users
6.2.6.5 Key Personnel
6.2.6.6 Analyst View
6.2.7 Immunovant Inc.
6.2.7.1 Overview
6.2.7.2 Top Products / Product Portfolio
6.2.7.3 Top Competitors
6.2.7.4 Target Customers/End-Users
6.2.7.5 Key Personnel
6.2.7.6 Analyst View
6.2.8 Pfizer Inc.
6.2.8.1 Overview
6.2.8.2 Top Products / Product Portfolio
6.2.8.3 Top Competitors
6.2.8.4 Target Customers/End-Users
6.2.8.5 Key Personnel
6.2.8.6 Analyst View
6.2.9 Others
7. RESEARCH METHODOLOGY
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL GRAVES’ DISEASE MARKET: INDUSTRY ANALYSIS
1.1 Market Overview and Ecosystem
1.2 Key Market Trends
1.2.1 Impact Analysis
1.3 Regulatory Landscape
1.4 Pipeline Analysis
1.5 Market Dynamics
1.5.1 Overview
1.5.2 Market Drivers
1.5.3 Market Restraints
1.5.4 Market Opportunities
2. GLOBAL GRAVES’ DISEASE MARKET (BY TREATMENT TYPE), VALUE ($MILLION), 2024-2035
2.1 Anti-Thyroid Medication
2.2 Radioactive Iodine Therapy
2.3 Surgery (Thyroidectomy)
2.4 Targeted Immunotherapies & Biologics
2.5 Ultrasound-Guided Thermal Ablation
3. GLOBAL GRAVES’ DISEASE MARKET (BY PATIENT AGE GROUP), VALUE ($MILLION), 2024-2035
3.1 Pediatrics
3.2 Adults
3.3 Geriatrics
4. GLOBAL GRAVES’ DISEASE MARKET (BY END USER), VALUE ($MILLION), 2024-2035
4.1 Hospitals
4.2 Specialty Clinics & Endocrinology Centers
4.3 Ambulatory Surgical Centers
4.4 Retail & Online Pharmacies
5. GLOBAL GRAVES’ DISEASE MARKET (BY REGION), VALUE ($MILLION), 2024-2035
5.1 North America
5.1.1 Market Dynamics
5.1.2 Market Sizing and Forecast
5.1.3 North America Graves’ Disease Market, by Country ($Million), 2024-2035
5.1.3.1 U.S.
5.1.3.2 Canada
5.2 Europe
5.2.1 Market Dynamics
5.2.2 Market Sizing and Forecast
5.2.3 Europe Graves’ Disease Market, by Country ($Million), 2024-2035
5.2.3.1 Germany
5.2.3.2 UK
5.2.3.3 France
5.2.3.4 Italy
5.2.3.5 Spain
5.2.3.6 Rest of Europe
5.3 Asia-Pacific
5.3.1 Market Dynamics
5.3.2 Market Sizing and Forecast
5.3.3 Asia-Pacific Graves’ Disease Market, by Country ($Million), 2024-2035
5.3.3.1 China
5.3.3.2 India
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.3.5 Rest-of-Asia Pacific
5.4 Latin America
5.4.1 Market Dynamics
5.4.2 Market Sizing and Forecast
5.4.3 Latin America Graves’ Disease Market, by Country ($Million), 2024-2035
5.4.3.1 Brazil
5.4.3.2 Mexico
5.4.3.3 Argentina
5.4.3.4 Rest-of-Latin America
5.5 Middle East and Africa
5.5.1 Market Dynamics
5.5.2 Market Sizing and Forecast
6. COMPETITIVE LANDSCAPE AND COMPANY PROFILES
6.1 Competitive Landscape
6.1.1 Mergers and Acquisitions
6.1.2 Partnership, Alliances and Business Expansion
6.1.3 New Offerings
6.1.4 Regulatory Activities
6.1.5 Funding Activities
6.2 Company Profiles
6.2.1 Horizon Therapeutics.
6.2.1.1 Overview
6.2.1.2 Top Products / Product Portfolio
6.2.1.3 Top Competitors
6.2.1.4 Target Customers/End-Users
6.2.1.5 Key Personnel
6.2.1.6 Analyst View
6.2.2 Novartis AG.
6.2.2.1 Overview
6.2.2.2 Top Products / Product Portfolio
6.2.2.3 Top Competitors
6.2.2.4 Target Customers/End-Users
6.2.2.5 Key Personnel
6.2.2.6 Analyst View
6.2.3 F. Hoffmann-La Roche Ltd.
6.2.3.1 Overview
6.2.3.2 Top Products / Product Portfolio
6.2.3.3 Top Competitors
6.2.3.4 Target Customers/End-Users
6.2.3.5 Key Personnel
6.2.3.6 Analyst View
6.2.4 Medtronic plc
6.2.4.1 Overview
6.2.4.2 Top Products / Product Portfolio
6.2.4.3 Top Competitors
6.2.4.4 Target Customers/End-Users
6.2.4.5 Key Personnel
6.2.4.6 Analyst View
6.2.5 GE HealthCare Technologies Inc.
6.2.5.1 Overview
6.2.5.2 Top Products / Product Portfolio
6.2.5.3 Top Competitors
6.2.5.4 Target Customers/End-Users
6.2.5.5 Key Personnel
6.2.5.6 Analyst View
6.2.6 Viridian Therapeutics Inc.
6.2.6.1 Overview
6.2.6.2 Top Products / Product Portfolio
6.2.6.3 Top Competitors
6.2.6.4 Target Customers/End-Users
6.2.6.5 Key Personnel
6.2.6.6 Analyst View
6.2.7 Immunovant Inc.
6.2.7.1 Overview
6.2.7.2 Top Products / Product Portfolio
6.2.7.3 Top Competitors
6.2.7.4 Target Customers/End-Users
6.2.7.5 Key Personnel
6.2.7.6 Analyst View
6.2.8 Pfizer Inc.
6.2.8.1 Overview
6.2.8.2 Top Products / Product Portfolio
6.2.8.3 Top Competitors
6.2.8.4 Target Customers/End-Users
6.2.8.5 Key Personnel
6.2.8.6 Analyst View
6.2.9 Others
7. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Graves’ Disease Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Graves’ Disease Market, 2024 and 2035
Figure: Global Graves’ Disease Market Key Trends, Impact Analysis
Figure: North America Graves’ Disease Market, $Million, 2024-2035
Figure: Europe Graves’ Disease Market, $Million, 2024-2035
Figure: Asia-Pacific Graves’ Disease Market, $Million, 2024-2035
Figure: Graves’ Disease Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Graves’ Disease Market, 2024 and 2035
Figure: Global Graves’ Disease Market Key Trends, Impact Analysis
Figure: North America Graves’ Disease Market, $Million, 2024-2035
Figure: Europe Graves’ Disease Market, $Million, 2024-2035
Figure: Asia-Pacific Graves’ Disease Market, $Million, 2024-2035
LIST OF TABLES
Table: Market Snapshot
Table: Market Dynamics
Table: Global Graves’ Disease Market (by Treatment Type), $Million, 2024-2035
Table: Global Graves’ Disease Market (by Patient Age Group), $Million, 2024-2035
Table: Global Graves’ Disease Market (by End User), $Million, 2024-2035
Table: Global Graves’ Disease Market (by Region), $Million, 2024-2035
Table: Market Snapshot
Table: Market Dynamics
Table: Global Graves’ Disease Market (by Treatment Type), $Million, 2024-2035
Table: Global Graves’ Disease Market (by Patient Age Group), $Million, 2024-2035
Table: Global Graves’ Disease Market (by End User), $Million, 2024-2035
Table: Global Graves’ Disease Market (by Region), $Million, 2024-2035
